H. Lee Moffitt Cancer Center and Research Institute

562 total trials 431 currently recruiting 62 completed

Trial Pipeline

RECRUITING Phase 2

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

NCT07476001

RECRUITING Phase 1

Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

NCT07194044

RECRUITING Phase 2

Digoxin Medulloblastoma Study

NCT06701812

RECRUITING Phase 1

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

NCT06961357

RECRUITING Phase 1

Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL

NCT07250087

RECRUITING Phase 2

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

NCT07276386

RECRUITING NA

Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs

NCT07222995

RECRUITING

A First-in-Human Study of FID-022 in Solid Tumor Patients

NCT07249775

RECRUITING Phase 1

Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)

NCT07047885

RECRUITING

Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

NCT07030400

RECRUITING NA

The MIND-BC Study: MIND Diet for Breast Cancer Cognition

NCT07018986

RECRUITING Phase 2

Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma

NCT07007273

RECRUITING Phase 2

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

NCT06745882

RECRUITING Phase 1

Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors

NCT06047977

RECRUITING Phase 2

Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

NCT06947083

RECRUITING NA

ProSalud in Latinos Living in Rural/Agricultural Communities Within Moffitt's Catchment Area

NCT07218848

RECRUITING NA

Creation of an Infrastructure to Support Delivery of mHealth Interventions for Cancer Patients

NCT06909357

RECRUITING Phase 2

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

NCT06553885

RECRUITING Phase 2

Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

NCT06760156

RECRUITING Phase 2

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

NCT06855212

RECRUITING Phase 2

Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer

NCT06833502

RECRUITING Phase 2

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

NCT06660355

RECRUITING Phase 1

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

NCT06238921

RECRUITING Phase 2

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

NCT06660368

RECRUITING Phase 2

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

NCT06511882

RECRUITING Phase 2

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

NCT06121180

RECRUITING Phase 1

Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

NCT06691035

RECRUITING Phase 1

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

NCT06193486

RECRUITING NA

Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening

NCT06745895

RECRUITING Phase 2

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

NCT06597565

RECRUITING NA

Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S)

NCT06560398

RECRUITING Phase 2

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

NCT06553872

RECRUITING Phase 2

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

NCT06409390

RECRUITING NA

Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer

NCT06497569

RECRUITING Early Phase 1

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

NCT06435351

RECRUITING Phase 2

App for Reducing Cravings to Smoke

NCT06088498

RECRUITING NA

Exercise Prehabilitation for Locoregional Esophageal Cancer

NCT06430346

RECRUITING Phase 2

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

NCT06295159

RECRUITING

Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)

NCT06423950

RECRUITING Phase 2

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

NCT06350318

RECRUITING NA

High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)

NCT06337552

RECRUITING Phase 1

Avapritinib With Decitabine in Patients With SM-AHN

NCT06327685

RECRUITING NA

Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer

NCT06423963

RECRUITING

Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)

NCT06305676

RECRUITING Phase 2

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

NCT06109467

RECRUITING Phase 2

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

NCT06144606

RECRUITING Phase 2

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

NCT06104592

RECRUITING Phase 1

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

NCT05809752

RECRUITING NA

Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)

NCT06001268

RECRUITING Phase 2

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

NCT05757219

RECRUITING Phase 1

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

NCT05581030

RECRUITING Early Phase 1

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

NCT05651828

RECRUITING

Outreach Core Activities

NCT05832177

RECRUITING

Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations

NCT05687188

RECRUITING Phase 2

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

NCT05732961

RECRUITING Phase 1

Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology

NCT05664178

RECRUITING Phase 1

CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

NCT05558124

RECRUITING Phase 2

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

NCT05751941

RECRUITING Phase 2

Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer

NCT05528133

RECRUITING

Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer

NCT05665504

RECRUITING Phase 2

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

NCT05526989

RECRUITING Phase 2

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

NCT05524935

RECRUITING Phase 1

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

NCT05504707

RECRUITING Phase 1

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

NCT05378464

RECRUITING Phase 2

Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma

NCT05301283

RECRUITING Phase 1

Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer

NCT05316129

RECRUITING Phase 1

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

NCT05024552

RECRUITING

Study of Screening Brain MRIs in Stage IV Breast Cancer

NCT05115474

RECRUITING Phase 1

Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases

NCT04923542

RECRUITING Early Phase 1

Using Aspirin to Improve Immunological Features of Ovarian Tumors

NCT05080946

RECRUITING Phase 2

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

NCT05325632

RECRUITING Phase 2

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

NCT05070403

RECRUITING Phase 2

Axitinib + Ipilimumab in Advanced Melanoma

NCT04996823

RECRUITING Early Phase 1

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

NCT04741997

RECRUITING Phase 1

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

NCT04588545

RECRUITING Phase 2

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

NCT04562129

RECRUITING

Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board

NCT04343365

RECRUITING

Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas

NCT04275557

RECRUITING Phase 2

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

NCT03495427

ACTIVE NOT RECRUITING NA

NutritiOUs fRuIts and veggieS to Improve Health: A Culinary Medicine Intervention

NCT06926972

ACTIVE NOT RECRUITING NA

Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center

NCT06712797

ACTIVE NOT RECRUITING Phase 2

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

NCT06734130

ACTIVE NOT RECRUITING Phase 2

Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)

NCT06519097

ACTIVE NOT RECRUITING Phase 1

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

NCT06236425

ACTIVE NOT RECRUITING Phase 1

Study of CG0070 After Transurethral Resection in Patients With IR NMIBC

NCT06253845

ACTIVE NOT RECRUITING

Investigation of MP Pollution in the Human Respiratory System and Its Relationship to Lung Cancer

NCT06530615

ACTIVE NOT RECRUITING NA

Breast Cancer Survivors RESET (Reducing Weight and Elevated Stress Levels Using Educational and Behavioral Tools): A Pilot, Feasibility Study

NCT07101861

ACTIVE NOT RECRUITING Phase 2

Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC

NCT06137274

ACTIVE NOT RECRUITING

REFLECT: Reproductive Education and Fertility Links for Cancer Treatment

NCT06199726

ACTIVE NOT RECRUITING NA

The MONITOR Study: Remote Monitoring Of a Nutrition Intervention To Optimize Treatment Response

NCT06050395

ACTIVE NOT RECRUITING Phase 1

Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC

NCT05768347

ACTIVE NOT RECRUITING NA

Senior Adult Hepatobiliary Prehab Study

NCT05921552

ACTIVE NOT RECRUITING NA

The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors

NCT05798780

ACTIVE NOT RECRUITING Phase 1

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

NCT05681780

ACTIVE NOT RECRUITING NA

Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy

NCT05763563

ACTIVE NOT RECRUITING NA

Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients

NCT05675059

ACTIVE NOT RECRUITING NA

Enhancing Long-Term Smoking Abstinence Among Cervical Cancer Survivors (Project ACCESS)

NCT05645146

ACTIVE NOT RECRUITING Phase 1

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

NCT05628883

ACTIVE NOT RECRUITING

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

NCT05692596

ACTIVE NOT RECRUITING NA

Early Supportive Care and Nutritional Support in Adults With Pancreatic Cancer

NCT05438927

Phase Distribution

PhaseTrial count
Phase 1 185
Phase 2 285
Phase 3 1

What the Pipeline for H. Lee Moffitt Cancer Center and Research Institute Shows

According to the ClinicalTrials.gov registry, H. Lee Moffitt Cancer Center and Research Institute is linked to 562 US clinical trials across every stage of research activity. Of those, 431 studies are currently recruiting — about 77% of the sponsor's indexed portfolio — and 62 are already marked complete, representing roughly 11% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for H. Lee Moffitt Cancer Center and Research Institute reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 470 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for H. Lee Moffitt Cancer Center and Research Institute is Prostate Cancer with 12 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial